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Abstract 
This study aimed to develop a modified Tessari method for producing more sclerosing foam in treatment of extensive 
venous malformations. Sclerosing foam was produced by using Tessari method and the modified Tessari method. The 
procedure of the later was as follows: prepared foam in a sclerosant–air ratio of 1:4; connected three disposable 10 ml 
syringes to two medical three‑way taps; drawn 4 ml of liquid sclerosant into one syringe and 16 ml averagely of air 
into the other two; then moved the plungers of all syringes back and forth for 20 times to produce sclerosing foam. 
The volume and foam half time (FHT) of foam produced by the two methods were compared. The average volume 
of sclerosing foam produced by Tessari method and the modified Tessari method were 9.8 and 19.7 ml, and assessed 
to have statistical difference. The FHT of foam produced by the two methods were 120 and 150 s, and assessed to 
have statistical difference. In conclusion, the modified Tessari method could produce more fresh and stable sclerosing 
foam.
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Background
During the treatment of venous malformations (VMs) 
using foam sclerotherapy, one of the most popular meth-
ods to produce foam was the Tessari method which used 
pumping cycles of liquid and air in-and-out of a double 
syringe system (Nastasa et al. 2015; Wolmann 2010; Tes-
sari 2001, 2005). In clinical treatment, sclerosing foam 
was prepared usually by using two 10 ml syringes; how-
ever, no more than 10 ml of sclerosing foam could be pro-
duced at a time in this way. Tessari method was originally 
used in the treatment of varicose veins, in most cases 
of which 10  ml of fresh sclerosing foam might be suffi-
cient (Tessari et  al. 2001). However, this volume might 
be insufficient in treating some VMs, especially when the 
region of lesion was extensive. Sufficient fresh sclerosing 
foam was needed for the treatment of extensive VMs.
There were several ways to get more fresh sclerosing 
foam, for example, producing foam once more, using big-
ger syringes or more operators and devices to produce 
simultaneously. However, all these methods had more or 
less defects. Here, we reported a modified Tessari method 
by using three 10 ml syringes which could produce more 
fresh foam at a time; the volume and the stability of foam 
produced by the two methods were compared. Foam half 
time (FHT), the time when half of the original liquid scle-
rosant was reverted to liquid state, was adopted to assess 
the stability of the foam.
Methods
Disposable 10  ml syringes, medical three-way taps and 
1 % lauromacrogol injection (Shanxi Tianyu Pharmaceu-
tical Co., Ltd.) were used in this study.
Procedure of Tessari method (Tessari et  al. 2001): 
drawn 2  ml of liquid sclerosant into one 10  ml syringe 
and 8 ml of air into the other 10 ml syringe; connected 
both syringes to a medical three-way tap; then, moved 
the plungers of both syringes back and forth for 20 times 
to produce sclerosing foam (Fig. 1).
Procedure of the modified Tessari method: drawn 4 ml 
liquid sclerosant into a 10 ml syringe and 16 ml air aver-
agely into the other two 10 ml syringes; then connected 
all syringes to two parallel medical three-way taps; then 
moved the plungers of all syringes back and forth for 20 
times to produce sclerosing foam (Fig. 2).
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Detection of the foam volume and the foam FHT: 
Once the foam was produced, it was immediately pushed 
into 10 and 20 ml scalar syringes respectively, the scalar 
syringes were placed vertically with the piston beneath. 
Macroscopic appearance of the foam was observed 
and volume of the foam was recorded. The foam in the 
syringes gradually separated into liquid and air, with the 
liquid sclerosant gathered at the bottom, when half vol-
ume of the liquid sclerosant was reverted, the time as 
FHT was recorded.
The detection above was measured respectively for 10 
times by the same operator. Each foam was prepared by 
using new sclerosant and all experiments were performed 
at an ambient temperature of 25 °C. Experimental values 
were compared by an independent-samples t test and 
analysed using SPSS 19.0. A p value ≤0.05 was consid-
ered significant.
Results
Right after production, the bubbles in foam were small 
and homogenous, when the foam began to re-convert to 
a liquid and air separated mix, foam bubbles got bigger 
and inhomogeneous, eventually foam converted to two 
components: liquid and air.
The average volume of sclerosing foam produced by 
Tessari method and the modified Tessari method were 
9.8 and 19.7 ml, and assessed to have statistical difference.
The FHT of foam produced by Tessari method and 
the modified Tessari method were 120 and 150  s, and 
assessed to have statistical difference (Table 1).
Discussion
Owing to its high efficiency, safety and economical 
advantages, foam sclerotherapy was widely used in treat-
ment of vascular abnormalities (Luebke and Brunkwall 
2008; Myers and Roberts 2009; Park et al. 2014; Van der 
Vleuten et al. 2014; Wolmann 2010). The high efficiency 
of foam sclerotherapy was closely related to the physical 
obstruction of blood flow and the displacing the intra-
vascular blood, which extended extent of contaction 
between the sclerosants and the vessel wall (Ikponmwosa 
et al. 2010; Wolmann 2010; Eckmann 2009; Van Deurzen 
et al. 2011). Therefore, the therapeutic effects related to 
whether the cavity of VMs could be replete by fresh scle-
rosing foam; In our clinical work, sometime more than 
10  ml fresh sclerosing foam was needed for extensive 
lesion, some authors found that 10  ml or more scleros-
ing foam was safety and efficacy, and no serious compli-
cations were observed (Stimpson et al. 2012; Chen et al. 
2015). In our experience, the most common complica-
tions were temporal pain with injection, swelling after 
injection and skin ulcer in some patients.
In our experimental and clinical experience, it was 
inconvenient to use 20 ml syringes to produce foam; and 
other authors had reported that 10 ml syringes were the 
best choice to produce foam considering normal han-
dling and foam stability (Wolmann 2010; Nastasa et  al. 
Fig. 1 Tessari method
Fig. 2 The modified Tessari method
Table 1 Average volume and foam half time (FHT) of foam 
produced by Tessari method and modified Tessari method






The average volume (ml)a 9.8 ± 0.2 19.7 ± 0.3
The FHT (s)a 120 ± 4.13 156 ± 6.85
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2015). Tessari method using two 10  ml syringes had 
become one of the most popular ways to produce foam. 
In clinical treatment, no more than 10 ml of foam could 
be produced at a time by using two 10 ml syringes, which 
might be insufficient in treating some extensive VMs.
To get more foam at a time, we might repeat the pro-
ducing procedure once more or add more operators and 
devices. But the process of injecting foam into extensive 
VMs might be interrupted. During the interval between 
two adjacent injections, the previous foam would be 
washed away by the blood. Therefore, injecting sufficient 
foam at a time into the cavity of extensive VMs produced 
better therapeutic effects (Van Deurzen et al. 2011). Fur-
thermore, there was another disadvantage when using 
the same syringe to prepare foam for the second time, it 
would be hard for the plunger to slide smoothly during 
preparation and injection. Adding more operators and 
devices to produce foam simultaneously meant to use 
more human and material resources. The modified Tes-
sari method could produce about 20 ml fresh foam at a 
time which, in our clinical experience, would be sufficient 
in treating some of extensive VMs.
FHT was a key and usually used parameter of the sta-
bility of sclerosing foam. In this study, the FHT of scle-
rosing foam produced by the modified Tessari method 
was longer than that by Tessari method, showing that 
the sclerosing foam produced by the modified Tessari 
method was more stable.
Conclusions
The modified Tessari method could produce more fresh 
and stable sclerosing foam at a time which was profitable 
in treating extensive VMs.
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